Aratana (PETX) Receives a Buy from Stifel Nicolaus


Stifel Nicolaus analyst Jonathan Block reiterated a Buy rating on Aratana (NASDAQ: PETX) yesterday and set a price target of $7. The company’s shares closed on Friday at $4.62.

According to TipRanks.com, Block is a 5-star analyst with an average return of 23.6% and a 75.8% success rate. Block covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA Inc, Idexx Laboratories, and Align Tech.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aratana with a $8.50 average price target.

See today’s analyst top recommended stocks >>

Based on Aratana’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $6.37 million. In comparison, last year the company had a GAAP net loss of $10.38 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aratana Therapeutics, Inc. operates as a development stage biopharmaceutical company, which focuses on the licensing, development and commercialization of innovative prescription medications for pets or pet therapeutics. It delivers prescription medicines that address significant medical needs for cats and dogs.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts